Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Progression-Free Survival
研究概览
简要总结
This study intends to include HER2-positive metastatic breast cancer patients (with or without brain metastasis) who have become resistant to previous treatment with trastuzumab. It will use pertuzumab in combination with pyrotinib and capecitabine to observe efficacy and safety. The choice of capecitabine as the chemotherapy drug is mainly based on the following reasons: ① it has been less commonly used as neoadjuvant treatment, making it less prone to cross-resistance; ② its oral formulation is convenient for administration, making it more acceptable to patients; ③ previous studies have shown good efficacy when combined with pyrotinib; ④ previous research in breast cancer patients with brain metastasis has also demonstrated certain effectiveness. It is hoped that through this study, preliminary evidence can be provided for the dual-target treatment of original Chinese drugs, as well as the treatment of HER2+ MBC after resistance to trastuzumab, and the addition of new data for patients with brain metastasis.
详细描述
Research Title A single-center, open-label, single-arm clinical study on the efficacy and safety of pertuzumab in combination with pyrotinib and capecitabine in the treatment of HER2-positive metastatic breast cancer patients who have developed resistance to previous trastuzumab treatment (with or without brain metastasis).
Study Drugs - Injectable pertuzumab: 50mg/vial - Pyrotinib: 80mg/tablet
Research Objective To evaluate the effectiveness and safety of pertuzumab in combination with pyrotinib and capecitabine in the treatment of HER2-positive metastatic breast cancer patients who have developed resistance to previous trastuzumab treatment (with or without brain metastasis). This study aims to provide preliminary evidence for the dual-target treatment of original Chinese drugs, and to add new data to the treatment model for trastuzumab-resistant HER2+ MBC and patients with brain metastasis.
Study Design A single-center, open-label, single-arm clinical study with a planned enrollment of 40 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients who can voluntarily sign an informed consent form;
- •Females aged ≥18 years at the time of signing the informed consent form;
- •ECOG PS performance status score between 0 and 2;
- •Patients histologically diagnosed with HER2-positive metastatic breast cancer, with or without brain metastasis, and with locally recurrent disease that cannot undergo curative surgery or radiation therapy;
- •Patients who experience relapse or metastasis within 1 year during or after (neo)adjuvant pertuzumab-based targeted therapy, or disease progression during first-line pertuzumab-based targeted therapy in advanced stages;
- •Patients who have received ≤1 regimen of previous pertuzumab-based targeted therapy for recurrent or metastatic disease;
- •Brain metastasis patients must meet the following criteria: stable previous brain metastasis treatment, untreated brain metastasis with no immediate need for local treatment, or progressive previous brain metastasis without immediate need for local treatment;
- •Left ventricular ejection fraction (LVEF) ≥50%;
- •Blood routine examination meets the following conditions: ① absolute neutrophil count (ANC) ≥1.5×109/L, ② platelet count ≥100×109/L, ③ hemoglobin ≥90g/L, ④ white blood cell count ≥3.0×109/L;
- •Liver function meets the following conditions: ① serum total bilirubin ≤1.5×ULN, or ≤3×ULN if liver metastasis is present, ② aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN, or ≤5×ULN if liver metastasis is present;
- •Renal function meets the following conditions: serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min (creatinine clearance calculated according to the Cockcroft-Gault formula);
- •Female patients who meet the following conditions can participate in this study: ① not fertile; ② fertility potential, with a negative pregnancy test result within 7 days before the first administration of the study drug, not breastfeeding, and consistently using highly effective contraceptive measures before study enrollment, throughout the study period, and within 6 months after the last administration of the study drug.
排除标准
- •Those who have previously received Inetetamab and/or pyrotinib treatment;
- •Those who have received capecitabine treatment within the past 2 weeks before randomization;
- •Patients with noticeable symptoms who require immediate local treatment for brain metastasis;
- •Exclusion criteria include having had or currently having any other malignant tumors within the past 5 years, except for cured cervical intraepithelial neoplasia, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (in situ carcinoma), and T1 (tumor invasion of the basement membrane)];
- •Exclusion criteria include having undergone major surgical procedures (including thoracotomy biopsy) within the past 4 weeks before randomization, suffering from major trauma (such as bone fracture), having unhealed wounds or fractures at the time of screening, or anticipating the need for major surgery during the study treatment period;
- •Exclusion criteria include having a history of myocardial infarction within the past 6 months; New York Heart Association (NYHA) class ≥ II congestive heart failure history, severe arrhythmia uncontrolled by medication (excluding atrial fibrillation, paroxysmal supraventricular tachycardia); known decrease in left ventricular ejection fraction (LVEF) to below 50% during or after previous trastuzumab treatment;
- •Known allergy to the drugs and excipients involved in this trial;
- •Known history of hypersensitivity reactions to any investigational drug;
- •Subjects deemed unfit for participation by other researchers.
研究组 & 干预措施
Label 1
Inetetamab plus pyrotiniband and capecitabine
干预措施: Inetetamab plus pyrotiniband and capecitabine (Drug)
结局指标
主要结局
Progression-Free Survival
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
It is an indicator of the long-term efficacy of the drug
次要结局
- Objective Response Rate(4 weeks)
- Disease Control Rate(4 weeks)
- Overall survival(the time from randomization to death from any cause, assessed up to 100 months.)
研究者
Yan Xue
Director of tumor hospital
Xi'an International Medical Center Hospital